Home › NDC Lookup › RxCUI directory › RxCUI 1039965

Sennosides, USP 17.2 MG Oral Tablet [Senokot] — RxCUI 1039965

RxNorm drug concept · Semantic branded drug
RxCUI 1039965 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1039965
Official nameSennosides, USP 17.2 MG Oral Tablet [Senokot]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asSenokot 17.2 MG Oral Tablet; SenokotXTRA 17.2 MG Oral Tablet
FDA products mapped1
Package NDCs mapped4
Reported Medicaid activity (SDUD)1,604 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Senna: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Senna typically produces a bowel movement within 6 to 12 hours. That's why most people take it at bedtime — so it can do its job overnight and you get results in the morning. If no...
  • How long does it take for senna to work?
  • Senna is designed for short-term, occasional use. You should not use it for more than 1 week unless your doctor specifically tells you it's okay. Using laxatives too often or for t...
  • Laxatives like senna can affect how your body absorbs other medications. To be safe, take senna at least 2 hours before or after any other drugs you use. It's always a good idea to...
📖 Read our full Senna guide →

🕸️ Concept Web — How Sennosides, USP 17.2 MG Oral Tablet [Senokot] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sennosides, USP 17.2 MG Oral Tablet [Senokot] RxCUI 1039965

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Sennosides, USP 36387
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Senokot 202961
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sennosides, USP Oral Tablet 373859
    • Sennosides, USP Oral Product 1159068
    • Sennosides, USP Pill 1159069
    • Sennosides, USP Oral Tablet [Senokot] 705972
    • Senokot Oral Product 1178946
    • Senokot Pill 1178947
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sennosides, USP 17.2 MG Oral Tablet SCD · 602802
  • Sennosides, USP 17.2 MG SCDC · 602801
  • Sennosides, USP Oral Tablet SCDF · 373859
  • Sennosides, USP Oral Product SCDG · 1159068
  • Sennosides, USP Pill SCDG · 1159069

Brand-Name Concepts

  • Sennosides, USP 17.2 MG [Senokot] SBDC · 1039964
  • Sennosides, USP Oral Tablet [Senokot] SBDF · 705972
  • Senokot Oral Product SBDG · 1178946
  • Senokot Pill SBDG · 1178947
  • Senokot BN · 202961

📦 FDA Products & Package NDCs

1 product · 4 package NDCs
4 package NDCs map to RxCUI 1039965 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
67618-0120-06 36 TABLET, FILM COATED in 1 BOTTLE (67618-120-06) Senokot Atlantis Consumer Healthcare, Inc. 1988-09-01
67618-0120-12 1 BLISTER PACK in 1 CARTON (67618-120-12) / 12 TABLET, FILM... Senokot Atlantis Consumer Healthcare, Inc. 1988-09-01
67618-0120-72 2 CARTON in 1 PACKAGE (67618-120-72) / 1 BOTTLE in 1 CARTON... Senokot Atlantis Consumer Healthcare, Inc. 2024-01-01
67618-0120-73 72 TABLET, FILM COATED in 1 BOTTLE (67618-120-73) Senokot Atlantis Consumer Healthcare, Inc. 2025-11-15
Observed labelers: Atlantis Consumer Healthcare, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.4163
Range $0.4163–$0.4163 · middle 50% $0.4163–$0.4163 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.